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ABSTRACT
Introduction Variation in test ordering is a major issue 
in Australia and globally with significant financial and 
clinical impacts. There is currently a lack of research 
identifying and remediating variation in the use of 
pathology tests in emergency departments (EDs). In 
2019, NSW Health Pathology introduced the Pathology 
Atlas of Variation that uses a data- driven tool (the Atlas 
Analytical Model) to investigate test order variation 
across New South Wales (NSW) and engage with local 
health districts (LHDs) to reduce variation. The objectives 
of this study are to evaluate whether this data- driven 
approach is associated with: (1) a reduction in test 
order variation; (2) improvements in patient outcomes 
and (3) cost benefits, for the five most frequent ED 
presentations.
Methods and analysis This is a large multisite 
study including 45 major public hospitals across 15 
LHDs in NSW, Australia. The Atlas Analytical Model 
is a data analytics and visualisation tool capable of 
providing analytical insights into variation in pathology 
investigations across NSW EDs, which will be used as 
feedback to inform LHDs efforts to reduce variation. 
Interrupted time series analyses using 2 years pre Atlas 
(2017–2018) and 2 years post Atlas (2021–2022) data 
will be conducted. Study data will be obtained by linking 
hospital and laboratory databases. Funnel plots will be 
used to identify EDs with outlying pathology test ordering 
practices. The outcome measures include changes 
in test ordering practices, ED length of stay, hospital 
admission and cost benefits (total pathology costs per ED 
encounter).
Ethics and dissemination The study has received 
ethical approval from the NSW Population and Health 
Service Research Ethics Committee (reference, 2019/
ETH00184). The findings of the study will be published 
in peer- reviewed journals and disseminated via 
presentations at conferences. We will also engage 
directly with key stakeholders to disseminate the findings 
and to inform policies related to pathology testing in  
the ED.
INTRODUCTION
Pathology tests are critical for patient care 
including for diagnosis, monitoring of treat-
ment outcomes and disease screening.1 
However, studies indicate substantial varia-
tion in the use of pathology tests in clinical 
practice.2 3 Variation in pathology investi-
gations can occur when patients with seem-
ingly similar health status (type and severity 
of illness) receive different pathology tests,4 
raising concerns about underutilisation of 
potentially useful tests or overutilisation of 
unnecessary tests.5
Variation in healthcare delivery in general 
is a major issue in Australia and globally with 
significant financial and clinical impacts.6–9 
There has been a concerted effort by health-
care services in numerous countries to 
Strengths and limitations of this study
 ► This will be the first state- wide study to evaluate the 
effects of a data- driven approach to reduce variation 
in emergency department (ED) pathology investiga-
tions and its potential patient and cost benefits in 
Australia.
 ► The project will establish pathology utilisation 
benchmarks through which EDs compare their test 
ordering practices relative to sites within their local 
health districts and similar peer groups.
 ► There are many other potential influences on the 
test ordering practices of clinicians in ED that may 
limit the impact of the Atlas project on reducing vari-
ation in test ordering.
 ► Although our analyses will adjust for several poten-
tial confounders available in our data sources, other 
unmeasured factors can potentially confound the 
study outcomes.
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investigate and address unwarranted variation through 
the development of healthcare ‘Atlas’ projects.10–12 
However, most of these projects have been conducted 
in primary care or focused broadly on healthcare varia-
tion. Few projects have targeted variation in pathology 
testing. Although there have been some studies indi-
cating a high level of variation in pathology test ordering 
practices13–15 in acute care hospitals, there is currently 
limited research identifying, measuring and remediating 
variation in the use of pathology tests, particularly in the 
emergency department (ED). A recent Australian study 
revealed significant variation in test ordering across EDs, 
with some EDs ordering consistently more tests that were 
not in line with best practice guidelines. For example, the 
likelihood of ordering C reactive protein (CRP) was 38.7 
times higher in one of the EDs compared with the ED 
with the lowest CRP testing,13 suggesting potential unwar-
ranted test ordering practices.
Unnecessary overutilisation of pathology tests can 
have significant consequences for patient flow in EDs, 
where pathology testing has a direct effect on ED length 
of stay (LOS).16 In one Australian study, the median 
LOS was shown to increase by up to 10 min for every five 
additional tests ordered and by up to 17 min for each 
30 min increase in test result turnaround time.16 Over-
utilisation of pathology tests can also have a negative 
impact on patient care, triggering a potential cascade of 
additional, unjustified and even invasive investigations, 
which may in turn lead to potentially harmful interven-
tions.17 18
Applying data analytics can play a key role in identi-
fying and reducing variation in pathology investigations 
by establishing benchmarks and uncommon variation 
that can be used to inform improved test requesting 
patterns and drive changes.3 19 20 Recently, NSW Health 
Pathology (NSWHP) in collaboration with the NSW 
Emergency Care Institute and eHealth Integrated 
Care introduced a pathology atlas project (hereafter 
referred to as the ‘NSWHP Atlas of Variation’). It is a 
state- wide health system quality improvement project 
that uses a data analytic tool (hereafter referred to as 
‘Atlas Analytical Model’) to investigate the variation that 
exists in New South Wales (NSW) and to engage with 
local health districts (LHDs) to reduce variation where 
it may be unwarranted. The fundamental premise of 
this approach is that identifying variation will promote 
an examination of its causes and any consequences of 
outlying ordering patterns. The project will use data as 
a catalyst to drive change in pathology ordering toward 
the most appropriate and efficient testing profile for 
a given patient scenario by allowing comparison of 
ordering patterns between sites.20 By identifying differ-
ences across sites with similar groups of patients, a 
discussion with LHDs can be initiated as to the reasons 
for variation in ordering, warranted versus unwarranted 
variation and its ultimate impact on patient outcomes 
and service costs.
Objectives
The NSW Pathology Atlas of Variation project will be 
conducted across NSW acute care settings (both EDs and 
intensive care units) over 5 years (2019–2024). However, 
this study protocol is focused on assessing the impact of 
the Atlas on ED pathology test ordering specifically the 
(1) five most frequent ED presentations and (2) results of 
the first 3 years of the project.
The objectives of this study are to evaluate whether a 
data- driven approach (ie, using Atlas Analytical Model 
to engage with LHDs) is associated with: (1) a reduc-
tion in test order variation; (2) improvements in patient 
outcomes through a reduction in ED LOS and a reduc-
tion in hospital admission rates16–18 and (3) cost benefits 
(total pathology costs per ED encounter).
METHODOLOGY
Study setting
The project will involve 45 major public hospital- based 
EDs across 15 LHDs in NSW, Australia. The number 
of ED presentations to these hospitals accounted for 
>70% of total ED presentations in NSW in 2017/2018.21 
According to the NSW peer groups for public hospitals 
classifications,22 12 of the study hospitals are classified as 
A1 (principal referral), 1 as A2 (paediatric specialist), 1 as 
A3 (ungrouped acute—tertiary referral), 10 as B1 (major 
hospital group 1), 8 as B2 (major hospitals group 2) and 
13 as C1 (district group 1). Principal referral hospitals 
are among the largest hospitals in the Australian health 
system providing a very broad range of services including 
24- hour ED, intensive care units and several other highly 
specialised units. With the exception of one hospital, all 
principal referral hospitals in NSW are included in the 
project. Paediatric hospitals have comparable facilities 
with those of principal referral hospitals, while major 
hospitals (B1 and B2) are relatively large but do not 
provide the range of services provided by the principal 
referral hospitals.23
Data sources
This study will use linked and deidentified administrative 
data to determine the effect of the Atlas. Comprehensive 
data on ED presentation characteristics, test utilisation 
and pathology costs will be obtained by linking two data-
bases: the NSWHP Data Warehouse and NSW Health’s 
Health Information Exchange (HIE).
The NSWHP Data Warehouse contains pathology order 
information including, but not limited to, patient demo-
graphics, medical reference number (MRN), test orders 
and results and times a specimen is received and a verified 
result made available. The data set also contains informa-
tion on pathology billing or costs aggregated at the ED 
encounter level. The HIE contains data on ED presenta-
tions including, but not limited to, patient demographics, 
patient MRN, patient visit/encounter ID, ED presenting 
problems, triage category, mode of arrival, patient dispo-
sition and throughput information such as arrival to 
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triage, arrival to see a nurse, arrival to see clinician and 
arrival to departure.
Data linkage will be a two- step process. First, the data 
sets will be linked via patient MRN, date of birth and ED 
presentation date and times. Second, all records matched 
in the first step will be evaluated if the pathology service 
date and time are occurring within ED arrival and depar-
ture time of the patient at a given hospital. The second 
step will ensure that the service provided is matched to 
the correct patient presentation.
Study population
The study population will consist of all patients who 
presented to the study EDs during the study period with 
the following five most common conditions: abdominal 
pain, chest pain, limb injury, respiratory disorder and 
fever. The choice of these ED presentations was based 
on the results of a pilot trial conducted in 2018 (Craig 
Scowen. The NSWHP Pathology Atlas of Variation: A pilot 
trial). According to the pilot trial, these five presentations 
accounted for 39% of the total ED presentations in 2018.
Study design
The objectives of the study will be assessed using an inter-
rupted time series (ITS), a type of quasiexperimental 
design, using both retrospective and prospective data. It is 
considered the best approach to evaluate the effect of an 
intervention at the population level when a randomised 
trial is not feasible.24 One of the strengths of ITS design is 
that it evaluates the effect of the intervention accounting 
for underlying preintervention trends in the outcome 
variables.24 25
The study will cover a 4- year period. The NSWHP Atlas 
of Variation was started in 2019 and the intervention 
activities will occur throughout 2019–2020. However, 
given 2019–2020 will be an intervention period, we will 
exclude the 2019–2020 data from the analysis. Therefore, 
the study will use 2 years (January 2017 to December 
2018) pre Atlas and 2 years (January 2021 to December 
2022) post Atlas data.
The Atlas Analytical Model
The Atlas Analytical Model employs a Microsoft Power 
business intelligence data analytics and visualisation 
tool capable of providing analytical insights into varia-
tion in pathology testing across NSW that can be used as 
feedback to inform LHDs efforts to reduce variation. It 
allows point and click selections across various elements 
to create a view relevant to a specific query or group. 
The model can be filtered by LHD, facility, peer group, 
presenting problem, age, gender, mode of arrival or sepa-
ration, triage category and ED LOS.
Engagement with LHDs and other key stakeholders
Figure 1 shows a framework for engagement with key 
stakeholders. A clinical working group consisting of 
pathologists, ED clinicians and analysts was formed to 
oversee the development, direction and communication 
of the Atlas data. This group recommended the analysis 
should be delivered in a group forum to ED clinicians, 
LHD executives and administrative teams in the initial 
phase. Through the co- design process with the NSW 
Emergency Care Institute, it emerged through interviews 
that ED clinicians did not generally spend time exploring 
Figure 1 A framework for engagement with various stakeholders involved in the NSW Pathology Atlas project. LHD, local 
health district.
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data visualisations for insights and a desktop tool was 
unlikely to drive wider change in an LHD without training 
and a substantial time commitment. Desktop dashboards 
are numerous within NSW Health and while they offer 
autonomy, findings may become isolated with one user. 
This, together with the time clinicians, would need to 
explore the data led the clinical working group to decide 
that sharing the analyses in a group would be the most 
effective first step.
The main objective of the Atlas Analytical Model is to 
raise awareness and generate discussion within an LHD. A 
localised summary analysis and key findings will be shared 
through clinical council meetings and cross- functional, 
multidisciplinary groups within LHDs. This approach 
will be trialled to identify the most effective medium for 
raising awareness and ongoing engagement within each 
LHD to build consensus and identify project groups to 
lead change.
Initial meetings will be conducted with senior members 
of the local pathology team to explore the Atlas data 
and prepare a session with the LHD clinical or executive 
team. This process is intended to uncover local nuances 
and context around findings relative to sites within the 
LHD and similar peer groups across the state. Then, LHD 
sessions will be held with ED clinicians, senior executive, 
financial or administrative teams. After reviewing data 
across the LHD and peer groups, the objective and output 
of the LHD session will be to develop a high- level action 




The primary outcome is a change in test ordering prac-
tices over time for selected tests where high outlying test 
ordering existed based on the initial analyses. The list 
of tests where high outlying test ordering exists will be 
identified using funnel plots as described in the ‘Anal-
ysis’ section. The secondary outcomes include patient 
(ED LOS and hospital admission) and cost benefits (total 
pathology costs per ED encounter). ED LOS is the length 
of time between arrival and ED disposition. Hospital 
admission will be defined as ED presentations subse-
quently leading to admission to inpatient wards or crit-
ical care wards such as intensive care or high dependency 
units. An ED episode of care with admission to the ED 
short stay unit but without subsequent admission to the 
hospital will not be considered as ‘hospital admission’.
Sample size consideration
We used chest pain data (one of the five ED presentations 
included in this study) to estimate the required sample 
size. Our previous study that evaluated the variation in 
test ordering practices for patients presenting to EDs with 
chest pain showed a considerable variation in the ordering 
of certain tests, particularly CRP, calcium, magnesium and 
phosphate, coagulation studies, lipase and blood gas.13 
The variation in the ordering of CRP was exceptionally 
high with 56% of patient presentations receiving CRP in 
one of the EDs compared with the population average of 
12%.13 A total of 750 patients presenting with chest pain 
per year from each hospital would be adequate to detect a 
reduction in CRP testing to within 15% of the population 
average testing rate, assuming a two- sided test with a 5% 
significance level and a power of 80%. An approximate 
similar sample size will be required for the other four 
ED presentations too. Given that the actual annual ED 
presentations due to the five conditions are much higher 
than the above estimate,26 there will be adequate sample 
size to address the objectives of the study.
Analysis
Funnel plots will be used to identify outlying test ordering 
practices by focusing on the top fifteen frequently ordered 
tests for each of the five conditions. Funnel plots, a type of 
statistical process control method, are used as a graphical 
aid representation of variation in an indicator of interest 
(eg, CRP testing rate) across different practices by plot-
ting the 95% (≈2 SD) and 99.8% (≈3 SD) control limits 
from the study population mean value and displaying an 
‘observed indicator’ against a measure of its precision 
(denominator size).27 High outlying test ordering for a 
given pathology test is defined as the testing rate above 
or below the 3 SD control limits from the mean study 
population testing rate (ie, the NSW average). Hospitals 
ordering a given test above 3 SD of the NSW average can 
be considered as over- testing, while those ordering below 
3 SD can be considered as under- testing. For tests where 
high outlying test ordering exists, we will compare the pre 
and post Atlas funnel plots to determine changes in the 
number of outlying hospitals (ie, above or below the 3 SD 
of the NSW average).
We will use two approaches to estimate the effects 
of the Atlas Analytical Model on each study outcome: 
segmented regression method and generalised regres-
sion methods. Segmented regression is one of the most 
commonly used approaches in ITS design. Its main advan-
tage is that it accounts for pre- existing trends in outcome 
variables. As segmented regression requires the outcome 
data to be aggregated into appropriate time points, we 
will divide the data into monthly intervals (eg, monthly 
CRP testing rate) over the study period. Thus, before 
and after Atlas periods will include 24 and 36 monthly 
time points, respectively, (excluding the 12- month transi-
tion period) and will constitute the two segments of the 
regression models. Segmented regression will be used 
to estimate the effect of the Atlas Analytical Model in 
the overall population (all study sites combined) as this 
approach does not account for potential clustering (that 
is the correlation between presentations to the same site). 
On the other hand, generalised regression methods, use 
patient- level data and can adjust for clustering effect and 
known confounders; it will, therefore, be used to corrob-
orate the results of the segmented regression.
Given the need for pathology tests and the patterns 
of testing for the paediatric population can be different 
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from the adults, we will conduct a sensitivity analysis by 
separating our data into paediatric versus non- paediatric. 
Other sensitivity analyses will also be conducted 
depending on the nature of the data (eg, excluding the 
paediatric hospital from the analysis).
Patient and public involvement
The project uses existing administrative hospital data sets. 
Therefore, this project does not involve any contact with 
patients or the public.
DISCUSSION
The potential significance of the study
TheNSWHP Atlas of Variation project has the potential 
to assist in reducing unnecessary variation in testing and 
promote quality use of pathology testing in NSW. The 
study findings will assist NSWHP in monitoring pathology 
services across EDs in NSW and enable ongoing improve-
ment of healthcare delivery across the state. The project 
will provide evidence that could also influence policy 
decisions on pathology testing in EDs and have substan-
tial financial implications for the government into the 
future.
Although the main purpose of this project will be for 
pathology service improvement in NSW, the project will 
serve as an exemplar for extension and development to 
include medical imaging and other acute care settings 
including intensive care units across Australia. This devel-
opment has the potential to have a major impact on the 
measurement of diagnostic quality and the appropriate-
ness of treatment and to shape decision- making across the 
health sector. The evidence generated can also be used to 
support and guide similar initiatives internationally.
Strengths and limitations of this study
To the best of our knowledge, this will be the first project 
to evaluate the effects of a data- driven approach to reduce 
variation in ED pathology investigations and the poten-
tial patient and cost benefits in Australia. While there 
have been numerous projects undertaken to reduce or 
rationalise test ordering, there has been little analysis of 
the impact of test ordering profiles in relation to patient 
and economic outcomes. The NSWHP Atlas of Variation 
is a state- wide multisite project including 45 hospitals. 
The project will establish pathology test utilisation bench-
marks through which EDs compare their test ordering 
practices relative to sites within their LHDs and similar 
peer groups. The benchmark metrics such as test volume, 
number of tests per encounter, number of requests per 
encounter and total pathology costs per encounter will be 
included. Pathology utilisation benchmarking can assist 
in harmonising test requesting practices and improving 
the quality of care across sites.28 29
The main limitation of the project is that there are 
many other potential influences on the test ordering 
practices of clinicians in ED beyond the Atlas project 
that may limit its impact on variation in test ordering.30 31 
These may need to be specifically identified and evalu-
ated during the implementation phase of the project.32 
In this study, we have only one paediatric hospital. The 
pathology test utilisation benchmarks that this project is 
aiming to establish may not apply to the single specialist 
paediatric hospital, which is likely to exhibit very different 
testing patterns compared with the general hospitals. We 
are aware that another quality improvement project to 
harmonise test requesting processes in hospital acute care 
is currently underway in one of the LHDs (which includes 
four of our study EDs). We will conduct sensitivity analyses 
(excluding these four sites) to check the robustness of our 
results. While our analyses will adjust for several potential 
confounding factors available in our data sources, being a 
type of observational study, other unmeasured factors can 
potentially confound the study outcomes. Therefore, any 
potential impact of the intervention in this project may 
not imply causation. From the data consistency perspec-
tive, our pilot project has identified some variations in data 
entry for ‘presenting problem’, one of our key variables in 
this project. Although most of the entries are consistent 
across the sites and there were only a few missing values 
for this variable, our pilot project has revealed some free- 
text entries and inconsistencies in the free- text entries of 
the type of presenting problem (eg, presentations with 
‘abdominal pain’ were entered as ‘pain—abdominal’, 
‘pain, abdominal’ or ‘abdo pain’ etc). Similar issues were 
identified in a previous NSW- based study.33 Our research 
team will work with clinicians and relevant personnel to 
standardise the terminologies used to describe this data 
field prior to conducting the analyses. It is important to 
remember that the 3 SD above or below the population 
average to identify over- testing or under- testing using 
funnel plots does not necessarily imply the inappropriate-
ness of test ordering. However, the findings of this study 
can be used as an important first step to investigate the 
appropriateness of testing. EDs can use the findings of 
the study to determine whether context- specific reviews 
are required to improve their test ordering practices.
Dissemination plan
We will disseminate the findings of the project to diag-
nostic informatics, health service/policymakers and 
broader audiences through conference presentations 
and peer- reviewed journal publications. We will follow 
the REporting of studies Conducted using Observational 
Routinely- collected health Data statement when writing 
publications.34 We will also engage directly with key stake-
holders including the NSW Ministry of Health, NSWHP 
and LHDs within NSW to disseminate the project find-
ings and to inform policies related to pathology testing 
in EDs.
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